OverviewSuggest Edit

Onxeo is a biotechnology company, that develops drugs for the treatment of orphan oncology diseases worldwide. The Company offers Beleodaq for the treatment of relapsed or refractory peripheral T-cell lymphoma. It also develops Beleodaq for the treatment of others liquid or solid tumors; AsiDNA, which is in Phase I clinical trial for the treatment of metastatic melanoma; Livatag that is in Phase III clinical trial to treat advanced primary liver cancer; and Validive, which is in Phase II clinical trial for the treatment of serious mucositis in patients treated for a head and neck cancer.

TypePublic
Founded1997
HQParis, FR
Websiteonxeo.com

Latest Updates

Employees (est.) (Dec 2020)30
Share Price (Feb 2021)€0.7
Cybersecurity ratingBMore

Key People/Management at Onxeo

Thomas Hofstaetter

Thomas Hofstaetter

Independent Director
Nicolas Trebouta

Nicolas Trebouta

Director - Representing Financière De La Montagne
Jean-Pierre Bizzari

Jean-Pierre Bizzari

Independent Director
Christine Garnier

Christine Garnier

Independent Director
Julien Miara

Julien Miara

Director - Representing Invus Public Equities Lp
Show more

Onxeo Office Locations

Onxeo has offices in Paris, New York and København
Paris, FR (HQ)
49 Boulevard du Général Martial Valin
København, DK
Fruebjergvej 3
New York, NY, US
315 Madison Ave #3006
Show all (3)

Onxeo Financials and Metrics

Onxeo Revenue

Market capitalization (12-Feb-2021)

53.7m

Closing stock price (12-Feb-2021)

0.7
Onxeo's current market capitalization is €53.7 m.
Show all financial metrics

Onxeo Cybersecurity Score

Cybersecurity ratingPremium dataset

B

89/100

SecurityScorecard logo

Onxeo Online and Social Media Presence

Embed Graph

Onxeo News and Updates

Onxeo Announces Formation of Scientific Advisory Committee of Leading Independent Experts

This newly formed committee of international specialists will advise on the scientific and clinical aspects related to the development of Onxeo’s current and future programs This newly formed committee of international specialists will advise on the scientific and clinical aspects related to the dev…

Onxeo Announces Completion of Patient Enrollment in DRIIV-1b Study and Positive Interim Results

PARIS, Nov. 09, 2020 (GLOBE NEWSWIRE) -- Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), (“Onxeo” or “the Company”), a clinical-stage biotechnology company specializing in the development of innovative drugs targeting tumor DNA Damage response (DDR), in particular against rare or resistant …

Onxeo Announces Enrollment of First Patient in Phase Ib/II Study Revocan

PARIS, Oct. 21, 2020 (GLOBE NEWSWIRE) -- Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), (“Onxeo” or “the Company”), a clinical-stage biotechnology company specializing in the development of innovative drugs targeting tumor DNA Damage response (DDR), in particular against rare or resistant …

Onxeo Reports its Financial Results for the First Half of 2020 and Provides an Update on its Activities

PARIS, Sept. 17, 2020 (GLOBE NEWSWIRE) -- Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), (“Onxeo” or “the Company”), a clinical-stage biotechnology company specializing in the development of innovative drugs targeting tumor DNA Damage response (DDR), in particular against rare or resistant…

Onxeo Reports Full-Year 2019 Financial Results and Provides Business Update

PARIS, April 17, 2020 (GLOBE NEWSWIRE) -- Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO - FR0010095596), (“Onxeo”, “the Company” or “the Group”), a clinical-stage biotechnology company specializing in the development of innovative drugs targeting tumor DNA Damage response (DDR) in oncology,…

Global Peripheral T-Cell Lymphoma (PTCL) Report 2018: Market Insights, Epidemiology and Market Forecast 2016-2027 Featuring AB Science, Celgene, CerRx & Onxeo S.A.

DUBLIN, Jan. 2, 2018 /PRNewswire/ -- The "Peripheral T-Cell Lymphoma (PTCL) - Market Insights, Epidemiology and Market Forecast-2027" drug pipelines has been added to ResearchAndMarkets.com's offering. Peripheral T-Cell Lymphoma (PTCL) - Market Insights, Epidemiology and Market...

Onxeo Blogs

Onxeo Reports its 2021 Half-Yearly Financial Results and Provides an Update on its Activities

Cash position of €24.5 million as of June 30, 2021, providing financial visibility until the end of 2022 and enabling […]

Onxeo Announces the Appointment of Dr. Shefali Agarwal as the Company’s Chairwoman of the Board

Danièle Guyot-Caparros, outgoing Chairwoman, remains an independent member of the Board of Directors and Chair of the Audit Committee   […]

Onxeo: Report on the Combined General Meeting of June 10, 2021

All resolutions voted in accordance with Board of Directors' recommendations Shefali Agarwal, MD, a clinical development expert in oncology, is […]

Onxeo Receives Notice of Allowance for a New Patent Broadening the Protection of AsiDNA™ in combination with a PARP Inhibitor in the United States

This new patent protects both AsiDNA™ in combination with a PARP inhibitor and the use of the combination for the […]

Onxeo’s Combined General Meeting on June 10, 2021 in camera: availability of preparatory documents and live webcast login information

Paris (France), May 21, 2021 - 5:45 p.m. CEST - Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO - FR0010095596), (“Onxeo”, […]

Publication of the 2020 Annual Financial Report

Paris (France), April 23, 2021 – 7.00 pm CEST - Onxeo S.A. (Euronext Growth Paris: ALONX, Nasdaq First North Copenhagen: […]
Show more

Onxeo Frequently Asked Questions

  • When was Onxeo founded?

    Onxeo was founded in 1997.

  • Who are Onxeo key executives?

    Onxeo's key executives are Thomas Hofstaetter, Nicolas Trebouta and Jean-Pierre Bizzari.

  • How many employees does Onxeo have?

    Onxeo has 30 employees.

  • Who are Onxeo competitors?

    Competitors of Onxeo include Jiangsu Hansoh Pharmaceutical Group, 3sbio and Kyowa Kirin.

  • Where is Onxeo headquarters?

    Onxeo headquarters is located at 49 Boulevard du Général Martial Valin, Paris.

  • Where are Onxeo offices?

    Onxeo has offices in Paris, New York and København.

  • How many offices does Onxeo have?

    Onxeo has 3 offices.